Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The association of exosomal RNA profiling and pathogenesis of moyamoya disease (MMD) and intracranial Atherosclerotic disease (ICAD) is unknown. In this study, we investigated the RNA profiles of sEV (small extracellular vesicles)/exosomes in patients with MMD and ICAD. Whole blood samples were collected from 30 individuals, including 10 patients with MMD, 10 patients with ICAD, and 10 healthy individuals. Whole transcriptome analysis was performed using the GeneChip WT Pico Reagent kit. Transcriptional correlation was verified using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The association between functional dysregulation and candidate RNAs was studied . In total, 1,486 downregulated and 2,405 upregulated RNAs differed significantly between patients with MMD and healthy controls. Differential expression of six circRNAs was detected using qPCR. Among these significantly differentially expressed RNAs, IPO11 and PRMT1 circRNAs were upregulated, whereas CACNA1F circRNA was downregulated. This is the first study showing that the differential expression of exosomal RNAs associated with MMD pathogenesis, such as overexpression of IPO11 and PRMT1 circRNAs, may be related to angiogenesis in MMD. The downregulation of CACNA1F circRNA may be related to vascular occlusion. These results propose the utility of exosomal RNAs as biological markers in MMD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291455PMC
http://dx.doi.org/10.1177/0271678X231162184DOI Listing

Publication Analysis

Top Keywords

patients mmd
12
rna profiling
8
sev small
8
small extracellular
8
extracellular vesicles/exosomes
8
moyamoya disease
8
differential expression
8
ipo11 prmt1
8
prmt1 circrnas
8
cacna1f circrna
8

Similar Publications

Moyamoya disease (MMD) is a rare and progressive cerebrovascular disorder characterized by stenosis of the internal carotid arteries and their major branches, leading to the development of abnormal collateral vessels. While MMD is traditionally associated with ischemic and hemorrhagic strokes, there is increasing recognition of the psychiatric symptoms that can accompany the disease, which significantly impact patient outcomes and complicate management. This case report presents a 30-year-old female with a history of recurrent ischemic strokes, hypertension, diabetes, and dyslipidemia, who initially presented with neurological symptoms including headache, left-sided weakness, and facial deviation.

View Article and Find Full Text PDF

Background: The cellular composition and molecular mechanisms of the pathological arteries in Moyamoya disease (MMD) remain poorly understood. To improve our understanding of pathogenesis in MMD, we aimed to comprehensively map the cellular composition and molecular alterations within the pathological arteries of patients with MMD.

Methods: Superficial temporal artery samples were collected from patients with MMD (n=2) and healthy controls (n=3), yielding a total of 26 371 cells that were used for single-cell RNA sequencing.

View Article and Find Full Text PDF

Background: Episodic migraine is a prevalent and disabling neurological disorder with a significant impact on quality of life and productivity. Preventive treatment aims to reduce the frequency, intensity, and disability associated with migraine attacks. However, the comparative efficacy and safety of available preventive strategies remain insufficiently addressed in the literature, especially in low- and middle-income countries.

View Article and Find Full Text PDF

Moyamoya disease (MMD) patients often experience cognitive dysfunction following vascular bypass surgery, with anesthesia potentially influencing recovery. This study aims to evaluate the effects of IVA and combined intravenous and inhalational anesthesia (CIA) on cognitive recovery in MMD patients and explore influencing factors. We included 120 MMD patients who underwent vascular bypass surgery from January 1, 2021, to January 31, 2023.

View Article and Find Full Text PDF

Background: Atogepant is a CGRP receptor antagonist used in prevention of migraine. This study assesses the safety and efficacy of this drug in management of migraine headaches.

Methods: PubMed, Scopus, Web of Science, and Cochrane CENTRAL were searched until March 24, 2025.

View Article and Find Full Text PDF